Drug intelligence / Profile preview

metoprolol + diltiazem

Development stage: Discontinued
Lead developer: US Pharmaceutical Holdings I
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

This is a combination of two cardiovascular medications - metoprolol (a beta-blocker) and diltiazem (a calcium channel blocker). While both drugs are individually used to treat conditions like hypertension and atrial fibrillation, their combination is generally approached with caution due to potentially serious drug interactions. The combination can cause enhanced negative effects on heart rate, blood pressure, and cardiac conduction, potentially leading to bradycardia, hypotension, heart block, or heart failure.

Targets

LTCC (Voltage-gated calcium channel (L-type))ADRB1 (β1)

Beyond the preview

Go deeper on metoprolol + diltiazem.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on metoprolol + diltiazem.

Explore the full profile